- 著者
- Eiichi Shimizu Yuta Yokobori Kazuki Miyazaki Kaori Ohara Megumi Fujii Tomoko Nishioka Noriko Fujita
- 出版者
- National Center for Global Health and Medicine
- 雑誌
- GHM Open (ISSN:2436293X)
- 巻号頁・発行日
- pp.2022.01008, (Released:2022-11-04)
- 参考文献数
- 20
- 被引用文献数
- 1
The introduction of health products to low- and middle-income countries (LMICs) is hindered by several barriers. Even when these barriers are overcome, improper use of health products can have a negative effect on health outcomes. Health products may go unused due to a mismatch of product needs as well as a lack of public infrastructure, spare parts and consumables, or trained technicians. This study presents a comprehensive framework of the essential steps for effectively delivering quality health products to people in need based on our document reviews and case studies. We divide the value chain of health products into seven steps: 1) situation analysis, 2) research and development, 3) regulatory authorization, 4) selection and prioritization, 5) public procurement, 6) distribution and storage, and 7) health service delivery. We find that the practice of undertaking one step at a time leads to enormous costs in terms of time and resources, often with little success. Failed attempts sometimes necessitate starting over from the beginning. Therefore, it is important to attempt each step while looking ahead to the end through the entire chain of seven steps. More in-depth analysis and lessons from best practices for each of the seven steps may need to be investigated further to consider possible interventions.
- 著者
- Mami Wakabayashi Yasunori Ichimura Eiichi Shimizu Tomoko Nishioka Yuzuru Kono Masahiko Doi Yuriko Egami Tomoka Kadowaki Hiroyasu Iso Noriko Fujita
- 出版者
- National Center for Global Health and Medicine
- 雑誌
- GHM Open (ISSN:2436293X)
- 巻号頁・発行日
- pp.2021.01032, (Released:2022-02-26)
- 参考文献数
- 20
- 被引用文献数
- 1
The World Health Organization (WHO) has been utilizing Emergency Use Listing (EUL) to expand access to medical products during the COVID-19 pandemic. EUL is a risk-based procedure for assessing and listing unlicensed vaccines, medicine, and in vitro diagnostics. To determine whether Japanese medical products acquired EUL relating to COVID-19, we conducted desk research as a part of a new project. Results showed that thirteen of twenty-eight in vitro diagnostic products were from China and three of ten vaccines on EUL were from India. However, only one vaccine manufactured in Japan was on EUL. A common weakness of Japanese companies in the global public procurement market was a lack of knowledge on qualification systems for medical products. We hypothesized holistic approaches from private companies and systematic supports from public sectors are required for a response to an emergency. These activities could lead to contribute to global health issues through sustainable businesses.